Having trouble accessing articles? Reset your cache.

Shire homes in

What convinced Shire to snag Arrowhead peptide platform to target rare diseases

Proof-of-concept data in cancer for Arrowhead Research Corp.'s peptide-based tissue targeting platform were good enough to get Shire plc on board to use the technology for rare diseases.

Last week, the companies partnered to use Arrowhead's Homing Peptide technology to discover peptide-drug conjugates. Arrowhead will identify peptides that selectively target an undisclosed tissue type, and Shire will provide the therapeutic payload.

Shire will have an option to license rights to develop and commercialize conjugates discovered under the deal. Arrowhead

Read the full 776 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers